-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunityBio (IBRX) Could Be 56% Below Fair Value Following ANKTIVA Trial And Launch News

Simply Wall St·11/18/2026 03:13:38
Listen to the news

ImmunityBio (IBRX) is back in focus after reporting positive final results from its pivotal QUILT-2.005 bladder cancer trial, alongside fresh ANKTIVA approvals and first commercial treatments in Israel and Europe.

ImmunityBio’s recent clinical and regulatory wins arrive after a sharp pullback, with a 30-day share price return down 31.81% and a 90-day return down 23%. At the same time, the stock shows very strong year-to-date share price gains and a 1-year total shareholder return close to tripling capital, which may suggest that traders are reassessing risk and timing rather than writing off the ANKTIVA story.

Spot opportunities beyond ImmunityBio by scanning a curated group of resilient healthcare names with 29 resilient stocks with low risk scores. These companies have lower risk profiles and potentially steadier share price behavior than single-drug stories.

After a huge swing up and a sharp pullback, ImmunityBio now sits at a level where opinions split. Is most of the ANKTIVA rerating already in the rear-view mirror, or is investors’ main upside still ahead?

Most Popular Narrative: 56% Undervalued

On the analyst consensus Narrative on Simply Wall St, ImmunityBio’s fair value is estimated at $14.25 versus a last close of $6.26. This frames the recent pullback as a move that still leaves a large gap between the current price and that modelled outcome.

The analysts have a consensus price target of $14.25 for ImmunityBio based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $16.0 and the most bearish reporting a price target of $12.0.

See why 24 investors see ImmunityBio as 56% undervalued.

Result: Fair Value of $14.25 (UNDERVALUED)

Still, the ImmunityBio narrative depends heavily on ANKTIVA, and any setback in new indications or slower physician uptake could quickly challenge the current fair value story.

Find out about the key risks to this ImmunityBio narrative.

Another View: What Multiples Say About ImmunityBio

ImmunityBio might look cheap on analyst fair value, yet the market is paying a steep revenue multiple. The stock trades on a P/S of 36.5x, compared with about 9.8x for the wider US Biotechs group and 9.3x for similar peers, while the fair ratio sits lower at 29x. That gap implies investors are already paying up for execution, so how comfortable are you with that kind of valuation stretch?

To see how this pricing stacks up against the underlying numbers, including that fair ratio level the market could move toward, See what the numbers say about this price — find out in our valuation breakdown..

NasdaqGS:IBRX P/S Ratio as at Nov 2026
NasdaqGS:IBRX P/S Ratio as at Nov 2026

Next Steps

Mixed views like this around ImmunityBio only matter if you put the numbers in context and stress test your own thesis. Move quickly, review both sides of the story, and ground your decision in the 3 key rewards and 2 important warning signs.

Looking For More Ideas Beyond ImmunityBio?

If ImmunityBio has your attention, do not stop here. Broader watchlists often reveal opportunities you would never spot by focusing on a single ticker.